ReviewMaturitas2019
Cardiovascular implications of gender-affirming hormone treatment in the transgender population.
Review in Maturitas, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Sex Hormone Supplementation and Cardiovascular Disease Risk.Medicina (Kaunas, Lithuania) · 2026Review
- Lifestyle behaviors and cardiovascular risk factors in transgender versus cisgender stroke survivors.PloS one · 2025Article
- Endocrine, gender dysphoria, and sexual function benefits of gender-affirming bilateral orchiectomy: patient outcomes and surgical technique.Sexual medicine · 2024Article
- The Role of the Athletic Trainer in Providing Care to Transgender and Gender-Diverse Patients: Considerations for Medical Affirmation-Part II.Journal of athletic training · 2024Review
- Dihydrotestosterone induces arterial stiffening in female mice.Biology of sex differences · 2024Article
- Sex and gender differences in risk scores for dementia and Alzheimer's disease among cisgender, transgender, and non-binary adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Observational
- Reporting Sex and Gender Differences in Cardiovascular Research.US cardiology · 2024Review
- Effectiveness and Safety of Different Estradiol Regimens in Transgender Women (TREAT Study): Protocol for a Randomized Controlled Trial.JMIR research protocols · 2023Article
- Risk Factors for Postsurgical Infections in Facial Feminization Surgery.Aesthetic plastic surgery · 2023Article
- Cardiovascular disease and feminizing gender-affirming hormone therapy: Implications for the provision of safe and lifesaving care.Current opinion in physiology · 2023Article
- Arterial Stiffness in Transgender Men Receiving Long-term Testosterone Therapy.Journal of the Endocrine Society · 2023Article
- 17β-Estradiol promotes sex-specific dysfunction in isolated human arterioles.American journal of physiology. Heart and circulatory physiology · 2023Article
- 'Don't think that we die from AIDS': Invisibilised uncertainty and global transgender health.Sociology of health & illness · 2023Article
- Rational drug repositioning for coronavirus-associated diseases using directional mapping and side-effect inference.iScience · 2022Article
- Body, metabolic and renal changes following cross-sex estrogen/progestogen therapy in a rodent model simulating its use by transwomen.Journal of endocrinological investigation · 2022Article
- Multicenter Analysis of Cardiometabolic-related Diagnoses in Transgender and Gender-Diverse Youth: A PEDSnet Study.The Journal of clinical endocrinology and metabolism · 2022Article
- Prostatic metaplasia of the vagina in transmasculine individuals.World journal of urology · 2022Article
- Queering Environmental Justice: Unequal Environmental Health Burden on the LGBTQ+ Community.American journal of public health · 2022Article
- Cardiometabolic Parameters Among Transgender Adolescent Males on Testosterone Therapy and Body Mass Index-Matched Cisgender Females.Transgender health · 2021Article
- Propensity Score Analysis Assessing the Burden of Non-Communicable Diseases among the Transgender Population in the United States Using the Behavioral Risk Factor Surveillance System (2017-2019).Healthcare (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Transgender men and women represent a growing population in the United States and Europe, with 0.5% of adults and 3% of youth identifying as transgender. Globally, an estimated 0.3-0.5% of the population identify as transgender. Despite the increasing percentage of individuals whose gender identity, gender expression and behavior differ from their assigned sex at birth, health outcomes in transgenders have been understudied. Many transgender people seek treatment with cross-sex hormone therapy starting from a young age and frequently at high doses in order to obtain the secondary sex characteristics of the desired gender. There is a need to understand the potential long-term health consequences of cross-sex hormone therapy, given that cardiovascular disease is the leading disease-specific cause of death in this population. This review discusses the cardiovascular risks of gender-affirming hormone treatments with respect to transgender women and transgender men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.